aibioAptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone
Tickers APVO
Aptevo filed a patent application covering a Nectin-4 x PD-L1 dual-targeting backbone that it says could support radiopharmaceuticals, T-cell engagers and other immune-based approaches.
Key facts
- Company
- Aptevo Therapeutics Inc. (NASDAQ: APVO)
- News type
- Company Updates
- Primary source
- Aptevo Therapeutics Inc. 8-K (2026-07-27)
Aptevo Therapeutics Inc. said on July 27, 2026 that it has filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone. The company says the backbone is designed to strengthen its oncology pipeline, expand partnering opportunities, and support several therapeutic approaches from one platform-derived innovation. The announcement is an exhibit to an 8-K.
Why the company says the filing matters
The release says that, instead of pursuing one product built for one use, the filing will protect a backbone that may be adapted into multiple cancer-fighting approaches. Aptevo says that gives it more ways to advance its own pipeline, expands opportunities to work with large pharmaceutical companies, and offers a new approach to treating solid tumors.
Jeff Lamothe, President and Chief Executive Officer of Aptevo, said: "This filing is about building value from our science and using it to create more ways to fight solid tumors."
Mary Janatpour, Ph.D., Chief Scientific Officer of Aptevo, said the backbone was designed to recognize two targets in solid tumors, Nectin-4 and PD-L1. According to the release, the same core approach can support radiopharmaceuticals, T-cell engagers and other immune-modulating therapies.
The release notes that radiopharmaceutical therapy is one potential application and an area of growing focus for the company. Pairing tumor-targeting constructs with radioligands is described as a way to deliver treatment activity directly to tumors.
The science the company describes
The release says Nectin-4 is found on several solid tumors, and that PD-L1 can be found both on tumor cells and on immune-suppressing cells within the tumor. By targeting both, Aptevo says it aims to direct treatment activity more selectively where it is needed, and to avoid normal tissues better than single-targeted agents. The company adds that targeting PD-L1 immune-suppressing cells is expected to enhance anti-tumor immunity.
The release also says the backbone shows how the ADAPTIR and ADAPTIR-FLEX platforms can be used to build different kinds of therapies. Aptevo says it can adjust how each construct is designed and add different therapeutic components depending on the goal. The company says the filing strengthens its intellectual property portfolio and supports a platform-driven strategy that could lead to collaborations.
Aptevo states in its About section that it is advancing APVO451, a nectin-4-targeted trispecific immunotherapy candidate for solid tumors, in preclinical development. The company is also pursuing strategic opportunities in radiopharmaceutical therapeutics.
The company and its financial position
The 10-K describes Aptevo as a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for cancer. It has two clinical candidates and six preclinical candidates, built on its ADAPTIR and ADAPTIR-FLEX platforms, which it wholly owns.
The lead clinical candidate, mipletamig, is a CD123xCD3 T cell engager being evaluated in the RAINIER trial, a two-part Phase 1b/2 trial for frontline acute myeloid leukemia with venetoclax and azacitidine. The 10-K says the RAINIER program was initiated in August 2024.
The XBRL data show research and development expense of $14.5 million for 2025, compared with $14.4 million for 2024. The net loss was $26.0 million in 2025 and $24.1 million in 2024. Operations used $25.6 million of cash in 2025 and $23.8 million in 2024. Year-end 2024 cash and cash equivalents were $8.7 million, a small cushion against $25.6 million of cash used in operations in 2025. The company has no product revenue.
What a patent filing does not mean
A patent application is a filing, not a granted patent, and the release does not say when or whether protection will be granted. It also gives no data of any kind on the backbone: no binding, cell or animal results, and no safety findings. The release names no drug candidate built on it and gives no date for starting a trial. Words such as "designed to" and "may be adapted" describe intent. The company's claims about avoiding normal tissues better than single-targeted agents are untested in this release. The partnering opportunities are a hope, with no partner or terms named. Meanwhile the company has to fund preclinical work in solid tumors on top of its leukemia trial, which points to further financing and possible dilution of current holders.